论文部分内容阅读
目的：评价ＥＬＦＰ方案治疗术后转移性胃癌的疗效、毒副反应。方法：表阿霉素５０ｍｇ／ｍ２，第１天；顺铂８０ｍｇ／ｍ２，第 １天，醛氢叶酸 １２５ｍｇ／ｍ２，第 １～５天；氟脲嘧啶 ５００ｍｇ／ｍ２，持续静脉点滴 １２，小时，第１～ ５天， ２１天为一周期。结果：４２例中ＣＲＳ例（１１．９％），ＰＲ１９例（４５．２％），总有效率５７．１％。中位缓解时间为４个月。初治。复治有效率分别为７３．７％和４３．５％，Ｐ＜０．０５。不同病理类型有效率３３．３％～１００％，Ｐ＜０．０５。不同转移部位有效率０—８０．０％，Ｐ＜０．０１本方案剂量限制性毒性为骨髓抑制５７．１％，均为Ⅰ度至Ⅱ度。心脏节律改变１１．９％，Ⅳ度仅１例。结论：ＥＬＦＰ方案治疗转移性胃癌疗效较好，毒副反应可耐受，有临床应用价值。
Objective: To evaluate the efficacy and toxicity of ELFP regimen in the treatment of metastatic gastric cancer. Methods: Epirubicin 50 mg/m2, on the first day; Cisplatin 80 mg/m2, on the first day, leucovorin 125 mg/m2, on days 1 to 5; fluorouracil 500 mg/m2, on-going intravenous drip for 12 hours , 1 to 5 days, 21 days for a cycle. Results: In 42 cases, CRS cases (11.9%), PR 19 cases (45.2%), total effective rate was 57.1%. The median time for remission is 4 months. Initial treatment. The retreatment efficiency was 73.7% and 43.5%, respectively, P<0.05. The effective rates of different pathological types ranged from 33.3% to 100%, P<0.05. The effective rate of different metastatic sites was 0-80.0%, P<0.01. The dose-limiting toxicity of this regimen was 57.1% for myelosuppression, which were all between I and II degrees. The heart rhythm changed by 11.9%, and only one case of IV degree. Conclusion: The ELFP regimen is effective in the treatment of metastatic gastric cancer, toxic and side effects can be tolerated, and has clinical application value.